Selicrelumab + Vanucizumab + Bevacizumab
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Solid Tumors
Conditions
Advanced/Metastatic Solid Tumors
Trial Timeline
Jan 25, 2016 → Oct 30, 2019
NCT ID
NCT02665416About Selicrelumab + Vanucizumab + Bevacizumab
Selicrelumab + Vanucizumab + Bevacizumab is a phase 1 stage product being developed by Roche for Advanced/Metastatic Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT02665416. Target conditions include Advanced/Metastatic Solid Tumors.
What happened to similar drugs?
0 of 2 similar drugs in Advanced/Metastatic Solid Tumors were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02665416 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced/Metastatic Solid Tumors